About
CONSTRUCTING THE PLAN FOR THE FUTURE IN BIOTECH PATENTS
While some may herald and embrace the next round of legal and legislative developments, the biotech industry instead anxiously encounters and anticipates a tumultuous period of confused edicts and erroneous decisions. It's what this industry has grown to expect in the ever-evolving, somewhat chaotic world of biotech patenting. This represents a time that requires nothing less than determined and confident decision making.
With all of these and many more issues in mind, the need and ability to maintain a superior level of expertise is essential. In-house counsel, attorneys, officers, executives, and IP experts must work together to decide what your company's next steps should be. To be successful, you need the most current and relevant information to navigate what are increasingly rocky waters.
The
American Conference Institute's Publication on
Biotech
Patents is fully dedicated to supplying the necessary materials that will better prepare you for today's conflicts - and to anticipate those of the future. The presentations include indispensable tools include, but are not limited to:
- Effective claiming for stem cell technology
- Executing patent strategies in the post-genome era
- Claiming inventions in 3D structure technology
- Negotiating worldwide biotech patent rights
- Exploring new methods of claim construction
- Recognizing the distinction between innovation and infringement
- Understanding potential legislation similar to Hatch-Waxman
- Implementing licensing strategies in light of recent case law developments
- Interpreting 35 USC §112 and written description requirements
- Defining "safe harbors" for collaborators
- Identifying crucial areas affected by Merck v. Integra
- Comprehending the doctrine of accidental anticipation
- Preparing for patent reform
Take this opportunity to get the information that you need from those on the cutting edge of law and science. Delegates will benefit from the extensive written materials prepared by the speakers especially for this conference by the speakers.
About
CONSTRUCTING THE PLAN FOR THE FUTURE IN BIOTECH PATENTS
While some may herald and embrace the next round of legal and legislative developments, the biotech industry instead anxiously encounters and anticipates a tumultuous period of confused edicts and erroneous decisions. It's what this industry has grown to expect in the ever-evolving, somewhat chaotic world of biotech patenting. This represents a time that requires nothing less than determined and confident decision making.
With all of these and many more issues in mind, the need and ability to maintain a superior level of expertise is essential. In-house counsel, attorneys, officers, executives, and IP experts must work together to decide what your company's next steps should be. To be successful, you need the most current and relevant information to navigate what are increasingly rocky waters.
The
American Conference Institute's Publication on
Biotech
Patents is fully dedicated to supplying the necessary materials that will better prepare you for today's conflicts - and to anticipate those of the future. The presentations include indispensable tools include, but are not limited to:
- Effective claiming for stem cell technology
- Executing patent strategies in the post-genome era
- Claiming inventions in 3D structure technology
- Negotiating worldwide biotech patent rights
- Exploring new methods of claim construction
- Recognizing the distinction between innovation and infringement
- Understanding potential legislation similar to Hatch-Waxman
- Implementing licensing strategies in light of recent case law developments
- Interpreting 35 USC §112 and written description requirements
- Defining "safe harbors" for collaborators
- Identifying crucial areas affected by Merck v. Integra
- Comprehending the doctrine of accidental anticipation
- Preparing for patent reform
Take this opportunity to get the information that you need from those on the cutting edge of law and science. Delegates will benefit from the extensive written materials prepared by the speakers especially for this conference by the speakers.
Contents & Contributors
INTELLECTUAL PROPERTY RIGHTS IN STEM CELL RELATED RESEARCH AND TOOLS
Richard Berman, Arent Fox PLLC
STEM CELL PATENTS: WHERE IS THE VALUE?
Cathryn Cambell, Of Counsel, Needle & Rosenberg PC
GENOMIC IP
Sander Rabin MD, JD, Whiteman Osterman & Hanna LLP
3-D STRUCTURES & THE TRILATERAL REPORT
Lisa A. Dixon, Vertex Pharmaceutical Incorporated
WORLWIDE BIOTECH PATENT RIGHTS AND ENFORCEMENT
Michelle Lewis, ZymoGenetics
RECENT DEVELOPMENTS IN PATENT CASE LAW: REVISITING MERCK, KNORR-BREMSE AND PHILLIPS
Robert H. Sloss, Farella Braun & Martel LLP
CLAIM CONSTRUCTION OF MARKUSH GROUPS AND OTHER ALTERNATIVE LIMITATIONS
Kevin Laurence, Stoel Rives LLP
FESTO AND ITS PROGENY – USING AND LOSING THE DOCTRINE OF EQUIVALENTS
Warren D. Woessner, JD, Ph.D., Schwegman Lundberg Woessner & Kluth
CREATING AND EXPLOITING RIGHTS IN PERSONALIZED MEDICINE
Michael J. Shuster, Ph.D., J.D., Fenwick & West LLP
DESIGNING A "HATCH-WAXMAN" PROTOCOL FOR FOLLO-ON BIOLOGICS
Mauricio Flores, Sheppard Mullin Richter & Hampton LLP
Deborah Shelton, Sheppard Mullin Richter & Hampton LLP
LICENSING STRATEGIES FOR BIOTECHNOLOGY AND THE EFFECT
OF ANTITRUST AND OTHER RECENT CASE LAW DEVELOPMENTS
Michael Flaschen, Amgen Corporation
Stephen Johnson, Kirkland & Ellis LLP
WRITTEN DESCRIPTION AND ENABLEMENT IN THE LIFE SCIENCES – A CASE FOR SPECIAL TREATMENT
Elizabeth Howard, Orrick Herrington & Sutcliffe LLP
MERCK V. INTEGRA: THE SUPREME COURT SPEAKS ON THE § 271 (e)(1) SAFE HARBOR
Karen I. Boyd, Fish & Richardson P.C.
THE ACCIDENTAL AND INHERENT ANTICIPATION DOCTRINE: WHERE DO WE STAND AND WHERE ARE WE GOING?
Anne Brown, Ph.D., Athersys Inc
PROPOSED PATENT REFROM LEGISTLATION AND RULE CHANGES
Michele A. Cimbala, Ph.D., Esq., Stern Kessler Goldstein & Fox PLLC
Publication Details